Latest Interviews
Showing 31–35 of 35 transcripts.
Clear all filters- Milken Institute57 min
The 2014 Atlanta Summit - - Government, Industry and a Healthier Future: A Leadership Forum
Mike Milken, Tom Frieden, Vince, Representative Kinston, Representative Bishop, Sue Siegel, Bob Hugin, Steve Knapp, Jack
Industry leaders from GE and Beckman Coulter, joined by Congressional representatives Sanford Bishop and Mike Kingston, convened to align public-private strategies for leveraging CDC data in pandemic preparedness and chronic disease management. Discussions highlighted a critical shift toward subscription-based surveillance funding and point-of-care diagnostic innovations, driven by the economic imperative to address the projected $1 trillion annual cost of chronic illnesses. Participants concluded by urging a reframing of public health as a driver of economic competitiveness, calling for rigorous data monetization to secure congressional support for prevention initiatives.
- Milken Institute1h 13m
Access to Global Capital Initiative: Corporate and Investor Roundtable
Tony Blair, Paul Kagame, Strive Masiyiwa, Seth Merrin, Mike Milken, Mindy Silverstein
At the Milken Institute's "Investing in Africa" working group, President Paul Kagame of Rwanda and Tony Blair outlined strategic partnerships with the Institute to accelerate capital flow into emerging markets through the new Access to Global Capital Initiative. The session highlighted Rwanda's 8% annual economic growth and regional integration efforts while presenting data indicating that emerging markets now hold a larger share of the global economy than the US, Europe, and Japan combined. With future plans to expand operations in Indonesia and convene international investors in East Africa, the group aims to leverage governance reforms and renewable energy projects to drive sustainable wealth creation across the continent.
- Milken Institute1h 11m
Lunch Panel: A Cure for What Ails Us: Celebrating the Impact of Science (updated II)
Nancy Brown, Francis Collins, Thomas Frieden, Andrew von Eschenbach, Michael Milken, Mike Milken, Tom Frieden, Andy Van Eschenbach, Jack Andreyka
A comprehensive analysis of global bioscience reveals a dramatic increase in life expectancy and major breakthroughs in disease eradication, such as the near-elimination of polio and HIV management through programs like PEPFAR. Despite these successes, the sector faces a critical funding crisis where declining NIH grant success rates and inflation-adjusted budget cuts threaten the pipeline of young researchers and the translation of genetic discoveries into new treatments. Strategic initiatives like the Brain Initiative, precision medicine efforts, and the shift toward prevention are now essential to address rising chronic disease burdens and sustain the bioscience industry as a primary driver of US economic growth.
- Milken Institute1h 3m
Credit Markets: What's Next?
Maria Boyazny, Richard Cantor, Joshua Friedman, Tony Ressler, Steven Tananbaum, David Warren, Michael Milken, Steve Tannenbaum, Maria Boiasni, Mike Milken
Six prominent credit executives from firms like Ares, GoldenTree, and Moody's convened to analyze the current credit market cycle, balancing optimistic views on RMBS and European bank debt against warnings of rising leverage and potential defaults. The panelists identified specific undervalued opportunities in structured products and illiquid assets while debating the structural risks posed by re-leveraging and the Federal Reserve's balance sheet expansion. Ultimately, the discussion emphasized a shift toward dynamic tactical asset allocation to navigate an environment where investors face a trade-off between immediate compensation and anticipated market corrections.
- Milken Institute1h 15m
The Promise of the Bioscience Century
Paul Irving, Mike Milken, Eric Cantor, Paul Chu, Jeff, Bernardo Zavala, Jr., Bernard Harris, Andy von Eschenbach, Peggy, Francis Collins, Chris Austin
This event analyzes the critical role of bioscience in driving global economic growth and societal well-being while highlighting China's aggressive $308 billion investment program that threatens to surpass U.S. leadership. Panelists discuss strategic institutional responses, such as DARPA's high-risk research model and the FDA's regulatory innovations, which have accelerated breakthroughs in prosthetics, personalized medicine, and disease prevention. However, fiscal constraints and shifting global demographics necessitate sustained bipartisan funding to preserve the United States' status as a central hub for scientific innovation and global health security.